We were interested to learn that Juvenescence Limited, a biotech and development company involved in the development of therapies that target the aging processes, has successfully raised $50 million in a series A financing round. Jim Mellon, the chairman of Juvenescence Limited, said, “We are delighted with the progress we have made and the faith…

Jim Mellon and Al Chalabi are back with another successful venture into the world of science investment. Following their acclaimed 2012 book “Cracking the code”, whose spotlight was on the life sciences industry, Juvenescence takes us on a compelling journey through the dawning market of longevity and rejuvenation biotechnology, which the authors predict will be…

Only two years ago, when I launched my advocacy website Rejuvenaction, I didn’t think I would read a book like Juvenescence so soon; yet, the topic of rejuvenation biotechnologies has already become mainstream enough to lead investors of the calibre of Jim Mellon and Al Chalabi to devote a whole book to it. As Juvenescence…

Many readers already know about billionaire entrepreneur Jim Mellon and his interest in rejuvenation biotechnology. For those who do not, we would like to introduce you to him and his exciting work. About Jim Mellon Jim Mellon is an entrepreneur and investor with interests in several sectors. He holds a Master’s degree from Oxford in…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD